MX357834B - Compuestos de tipo isocumarina sustituidos para tratar la atrofia muscular espinal. - Google Patents

Compuestos de tipo isocumarina sustituidos para tratar la atrofia muscular espinal.

Info

Publication number
MX357834B
MX357834B MX2014008875A MX2014008875A MX357834B MX 357834 B MX357834 B MX 357834B MX 2014008875 A MX2014008875 A MX 2014008875A MX 2014008875 A MX2014008875 A MX 2014008875A MX 357834 B MX357834 B MX 357834B
Authority
MX
Mexico
Prior art keywords
compounds
muscular atrophy
spinal muscular
treating spinal
treating
Prior art date
Application number
MX2014008875A
Other languages
English (en)
Other versions
MX2014008875A (es
Inventor
Chen Guangming
Mitchell Karp Gary
Li Chunshi
Narasimhan Jana
Naryshkin Nikolai
L Weetall Marla
Welch Ellen
Dakka Amal
Zhao Xin
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Publication of MX2014008875A publication Critical patent/MX2014008875A/es
Publication of MX357834B publication Critical patent/MX357834B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/76—Benzo[c]pyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)

Abstract

Se proporcionan en la presente compuestos, composiciones del mismo y usos con los mismos para tratar la atrofia muscular espinal.
MX2014008875A 2012-01-26 2013-01-25 Compuestos de tipo isocumarina sustituidos para tratar la atrofia muscular espinal. MX357834B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261591102P 2012-01-26 2012-01-26
PCT/US2013/023067 WO2013112788A1 (en) 2012-01-26 2013-01-25 Compounds for treating spinal muscular atrophy

Publications (2)

Publication Number Publication Date
MX2014008875A MX2014008875A (es) 2014-10-14
MX357834B true MX357834B (es) 2018-07-26

Family

ID=48873933

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014008875A MX357834B (es) 2012-01-26 2013-01-25 Compuestos de tipo isocumarina sustituidos para tratar la atrofia muscular espinal.

Country Status (12)

Country Link
US (1) US9399649B2 (es)
EP (1) EP2809322B9 (es)
JP (2) JP6193888B2 (es)
KR (1) KR102064624B1 (es)
CN (1) CN104203239B (es)
BR (1) BR112014018027B1 (es)
CA (1) CA2862084C (es)
EA (1) EA028344B1 (es)
ES (1) ES2733644T3 (es)
MX (1) MX357834B (es)
PL (1) PL2809322T3 (es)
WO (1) WO2013112788A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE47689E1 (en) 2011-12-30 2019-11-05 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
ES2733644T3 (es) * 2012-01-26 2019-12-02 Ptc Therapeutics Inc Compuestos para tratar atrofia muscular espinal
JP6092897B2 (ja) 2012-02-10 2017-03-08 ピーティーシー セラピューティクス， インコーポレイテッド 脊髄性筋萎縮症を治療するための化合物
EA029155B1 (ru) 2012-03-01 2018-02-28 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Соединения для лечения спинальной мышечной атрофии
CA2868026C (en) 2012-03-23 2021-02-16 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
MX2015008146A (es) * 2012-12-24 2016-01-20 Univ Ramot Agentes para tratar enfermedades geneticas derivadas de mutaciones sin sentido y metodos para identificarlas.
CN105392790B (zh) 2013-08-19 2019-04-19 豪夫迈·罗氏有限公司 4H-吡啶并[1,2-a]嘧啶-4-酮化合物制备用于预防或治疗癌症的药物的用途
WO2015095446A1 (en) * 2013-12-19 2015-06-25 Ptc Therapeutics, Inc. Methods for modulating the amount of rna transcripts
EP3082820B1 (en) 2013-12-19 2022-07-20 PTC Therapeutics, Inc. Methods for modulating the amount of rna transcripts
DK3143025T3 (da) * 2014-05-15 2019-12-09 Hoffmann La Roche Forbindelser til behandling af spinal muskelatrofi
US10882868B2 (en) 2014-05-15 2021-01-05 Hoffmann-La Roche Inc. Compounds for treating spinal muscular atrophy
EP4249472A3 (en) 2015-05-30 2023-12-13 PTC Therapeutics, Inc. Methods for modulating rna splicing
JP6659841B2 (ja) * 2015-11-12 2020-03-04 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 脊髄性筋萎縮症を処置するための組成物
CA3005434C (en) 2015-11-16 2024-09-10 Ohio State Innovation Foundation METHODS AND COMPOSITIONS FOR TREATING DISORDERS AND DISEASES USING MOTOR NERVE SURVIVAL PROTEIN (MNS)
EP3386978B1 (en) 2015-12-10 2021-01-27 H. Hoffnabb-La Roche Ag Bridged piperidine derivatives
CN110946865B (zh) 2015-12-10 2024-01-26 Ptc医疗公司 用于治疗亨廷顿病的方法
JP6738044B2 (ja) * 2016-07-22 2020-08-12 Jnc株式会社 ベンゾピラン骨格を有する液晶性化合物、液晶組成物、および液晶表示素子
WO2018098446A1 (en) 2016-11-28 2018-05-31 Ptc Therapeutics, Inc Methods for modulating rna splicing
EP3634953B1 (en) 2017-06-05 2024-01-03 PTC Therapeutics, Inc. Compounds for treating huntington's disease
BR112019026508A2 (pt) 2017-06-14 2020-07-14 Ptc Therapeutics, Inc. métodos para modificar o splicing do rna
MX2019015578A (es) 2017-06-28 2020-07-28 Ptc Therapeutics Inc Metodos para tratar la enfermedad de huntington.
CN111163838B (zh) 2017-06-28 2023-03-28 Ptc医疗公司 用于治疗亨廷顿氏病的方法
RU2020105929A (ru) 2017-08-04 2021-09-06 Скайхоук Терапьютикс, Инк. Способы и композиции для модулирования сплайсинга
JP7399870B2 (ja) 2018-03-27 2023-12-18 ピーティーシー セラピューティクス， インコーポレイテッド ハンチントン病を処置するための化合物
EP3814360B8 (en) 2018-06-27 2024-11-06 PTC Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
CA3105174A1 (en) * 2018-06-27 2020-01-02 Reborna Biosciences, Inc. Prophylactic or therapeutic agent for spinal muscular atrophy
KR20210038845A (ko) 2018-06-27 2021-04-08 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료를 위한 헤테로아릴 화합물
PL3814357T3 (pl) 2018-06-27 2024-09-16 Ptc Therapeutics, Inc. Związki heterocykliczne i heteroarylowe do leczenia choroby huntingtona
EP3920926A4 (en) 2019-02-05 2022-10-19 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
JP7603592B2 (ja) 2019-02-05 2024-12-20 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングを調節するための方法および組成物
WO2020163544A1 (en) 2019-02-06 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
CN119638696A (zh) 2019-02-06 2025-03-18 斯基霍克疗法公司 用于调节剪接的方法和组合物
CN114245794B (zh) 2019-05-13 2024-09-13 Ptc医疗公司 用于治疗亨廷顿氏病的化合物
US11129829B2 (en) 2019-06-17 2021-09-28 Skyhawk Therapeutics, Inc. Methods for modulating splicing
CN121488042A (zh) * 2023-06-09 2026-02-06 豪夫迈·罗氏有限公司 诱导型基因表达系统

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5854142B2 (ja) * 1975-04-16 1983-12-02 株式会社興人 イソカルボスチリル誘導体の製造方法
US5089633A (en) * 1987-04-28 1992-02-18 Georgia Tech Research Corporation Substituted isocoumarins
US6180625B1 (en) * 1998-03-24 2001-01-30 Novo Nordisk A/S Heterocyclic compounds regulating clotting
WO2003005025A1 (en) * 2001-07-03 2003-01-16 Biovitrum Ab Methods for identifying compounds modulating the activity of ppar-gamma
GB0205281D0 (en) * 2002-03-06 2002-04-17 Novartis Ag Organic compounds
US20040077529A1 (en) 2002-06-10 2004-04-22 Per-Fredrik Lehmann Urotensin II receptor agents
JP4616643B2 (ja) * 2002-06-28 2011-01-19 バーテックス ファーマシューティカルズ インコーポレイテッド カスパーゼインヒビターおよびそれらの用途
JP2004168707A (ja) * 2002-11-20 2004-06-17 Bayer Cropscience Ag イソチアゾリルベンゾオキサジン誘導体および病害防除剤
US9068234B2 (en) 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
EP1646615B1 (en) 2003-06-06 2009-08-26 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as modulators of atp-binding cassette transporters
WO2006078834A1 (en) 2005-01-21 2006-07-27 Janssen Pharmaceutica N.V. Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors
KR100781704B1 (ko) * 2005-04-20 2007-12-03 에스케이케미칼주식회사 피리딘 유도체와 이의 제조방법, 및 이를 포함하는약제조성물
AR059339A1 (es) 2006-02-09 2008-03-26 Chugai Pharmaceutical Co Ltd Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene
US8337941B2 (en) 2006-07-27 2012-12-25 The Trustees Of Columbia University In The City Of New York Fluorescent substrates for monoamine transporters as optical false neurotransmitters
KR20080091949A (ko) 2007-04-10 2008-10-15 에스케이케미칼주식회사 락톤형 피리딘 화합물을 포함하는 허혈성 질환의 예방 및치료용 약학조성물
JP5276878B2 (ja) 2007-09-27 2013-08-28 富士フイルム株式会社 ベンゾオキサジノン系化合物の製造方法
US8633019B2 (en) * 2008-05-27 2014-01-21 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
WO2010019243A1 (en) 2008-08-13 2010-02-18 Ptc Therapeutics, Inc. Methods for treating viral infections
USRE47689E1 (en) 2011-12-30 2019-11-05 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
ES2733644T3 (es) * 2012-01-26 2019-12-02 Ptc Therapeutics Inc Compuestos para tratar atrofia muscular espinal
JP6092897B2 (ja) 2012-02-10 2017-03-08 ピーティーシー セラピューティクス， インコーポレイテッド 脊髄性筋萎縮症を治療するための化合物
EA029155B1 (ru) 2012-03-01 2018-02-28 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Соединения для лечения спинальной мышечной атрофии
CA2868026C (en) 2012-03-23 2021-02-16 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy

Also Published As

Publication number Publication date
CN104203239A (zh) 2014-12-10
JP2015511224A (ja) 2015-04-16
EP2809322A4 (en) 2015-12-23
WO2013112788A1 (en) 2013-08-01
HK1202069A1 (en) 2015-09-18
EA028344B1 (ru) 2017-11-30
EP2809322B9 (en) 2019-10-30
EA201491412A1 (ru) 2014-12-30
CA2862084C (en) 2021-05-11
US20150126515A1 (en) 2015-05-07
BR112014018027B1 (pt) 2020-10-27
CA2862084A1 (en) 2013-08-01
KR20140127271A (ko) 2014-11-03
EP2809322B1 (en) 2019-05-15
JP6193888B2 (ja) 2017-09-06
ES2733644T3 (es) 2019-12-02
PL2809322T3 (pl) 2019-11-29
CN104203239B (zh) 2017-09-08
US9399649B2 (en) 2016-07-26
BR112014018027A8 (pt) 2017-07-11
EP2809322A1 (en) 2014-12-10
JP2017171667A (ja) 2017-09-28
KR102064624B1 (ko) 2020-01-09
BR112014018027A2 (es) 2017-06-20
MX2014008875A (es) 2014-10-14

Similar Documents

Publication Publication Date Title
MX2022011699A (es) Compuestos para tratar la atrofia muscular espinal.
MX357834B (es) Compuestos de tipo isocumarina sustituidos para tratar la atrofia muscular espinal.
MX2014010406A (es) Compuestos para tratar atrofia muscular espinal.
MX358514B (es) Compuestos para tratar la atrofia muscular espinal.
PH12014502704B1 (en) Compounds and compositions for modulating egfr activity
WO2014052836A3 (en) Methods and compositions for treating infection
GEP201706754B (en) Proliposomal testosterone formulations
MX359769B (es) Metodos para descelularizar huesos.
AU2013225816A8 (en) Compositions and methods for treating Type III Gaucher Disease
MX367393B (es) Composiciones antifungicas para el tratamiento de piel y uñas.
WO2012017321A3 (en) Treatment for dyslipidemia
IL237542B (en) Amphiphilic compounds, their preparations and uses
GEP201706708B (en) Isoxazolidine derivatives
MX356102B (es) Compuestos y métodos para tratar leucemia.
IL267888B (en) Amphiphilic compounds, their preparations and uses
IL237540A0 (en) Amphiphilic compounds, their preparations and uses
IL237538A0 (en) Amphiphilic compounds, their preparations and uses
IL237539A0 (en) Amphiphilic compounds, their preparations and uses
MX2013008559A (es) Derivados de leptina.

Legal Events

Date Code Title Description
FG Grant or registration